Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, SCZ

Petalo.ai Announces its Launch, Delivers a Revolution in Senior Care

ROCKVILLE, Md., Aug. 14, 2019 /PRNewswire/ -- Petalo.ia, a company focused on passionately unscrambling senior care operations through technology, announces its official launch and market entry.

Founded by senior care industry veterans Camille Roussel and Jason Gottschalk, Petalo.ai's service is a voice-first customer engagement platform that increases customer satisfaction and dramatically improves staff efficiency.  

Petalo, the company's namesake platform, harnesses Amazon's Alexa to engage residents with seamless and personalized interactions. The platform enterprise solutions include,

Residents can instantaneously communicate requests to staff, access information on community's services and staff, and get up-to-date listings for events and menus. Petalo engages with guests more quickly and accurately than other traditional methods. The immediate feedback provides faster response times and greater peace of mind, increasing customer satisfaction.

Petalo delivers real-time information ensuring staff is informed with the latest requests and empowered to prioritize their workflows. Rather than walking blindly into resident rooms, staff arrived equipped to deal with issues on first contact. The care team shares a common view of requests, which allows them to engage in decision making and triage instead of feeling micromanaged by the systems around them.

"We are excited to bring the Petalo platform to the senior care industry," Petalo.ai CEO, Camille Roussel said. "For over a decade we struggled on the provider side with challenges in the technology available to care providers. The systems available were frustrating for our staff to use and failed to deliver value to our customers. We created Petalo.ai to modernize senior care operations and allow leadership teams to delight their residents, guests, and staff."

For more information about Petalo.ai and the Petalo platform, please visit petalo.ai.

Headquartered in Rockville, Maryland, Petalo.ai was founded in 2018 by senior care industry veterans, Camille Roussel and Jason Gottschalk. The company was launched with the goal of solving some of the industry's largest challenges - one being the ability to leverage technology and expertise to create a seamless experience for the end user at senior care facilities. For more information, please visit petalo.ai.

MEDIA CONTACT:                                                                             
Lauren Hoke
RMR & Associates Inc.
(301) 230-0045 x101


SOURCE Petalo.ai

These press releases may also interest you

at 08:20
Portola Pharmaceuticals, Inc. today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of experience in the discovery and development of high impact medicines....

at 08:17
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Christopher D. Roberts, Ph.D., as Chief Scientific...

at 08:15
Menarini Silicon Biosystems today announces the launch of the MSBiosuite, a cloud-based data analysis solution that completes the company workflow* for liquid biopsy and formalin-fixed paraffin embedded (FFPE) tissue analysis, and provides a powerful...

at 08:15
Trovagene, Inc. , a clinical-stage, Precision Cancer Medicinetm oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today announced the...

at 08:15
At a time when more and more people are turning to assisted reproductive technologies (ART) to start or grow their families, the importance of choosing a fertility center that maintains the highest quality, safety, and security standards cannot be...

at 08:10
MicuRx Pharmaceuticals, Inc., today announced positive top-line results from the pivotal Phase 3 clinical trial in China for its lead antibacterial drug candidate contezolid (MRX-I) in adult patients with complicated skin and soft tissue infection...

News published on 14 august 2019 at 11:30 and distributed by: